Ginkgo Bioworks

205 articles about Ginkgo Bioworks

• Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

  5/8/2023

  Ginkgo Bioworks today announced a new partnership with Boehringer Ingelheim.

• 

  Boehringer Ingelheim to Mine Ginkgo’s Molecules in $406M Undruggable Targets Deal

  5/8/2023

  Partnership seeks to identify novel therapeutic molecules to address diseases with high unmet patient needs. It’s the second target discovery company to link with BI in the last month.

• Ginkgo Bioworks Announces Appointment of Steven P. Coen as Chief Accounting Officer

  5/5/2023

  Ginkgo Bioworks Holdings, Inc.today announced the appointment of Steven P. Coen, CPA, a seasoned finance executive with more than 30 years of public accounting and corporate finance leadership experience, as Chief Accounting Officer ("CAO"), effective May 15, 2023.

• Ginkgo Bioworks Announces Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

  5/4/2023

  Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 16-20, in Los Angeles.

• Ginkgo Bioworks Announces Date of First Quarter 2023 Results Presentation

  5/3/2023

  Ginkgo Bioworks today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2023.

• Visolis and Ginkgo Bioworks Announce Partnership to Improve Microbial Strain for Bio-Isoprene and Sustainable Aviation Fuel Production

  4/24/2023

  Visolis today announced a partnership with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity.

• Ginkgo Bioworks Previews Today's Annual Ferment Conference - April 19, 2023

  4/19/2023

  Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment.

• Cambrium and Ginkgo Bioworks Complete Successful Collaboration on Data-Driven Cell Factory Engineering

  4/18/2023

  Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the successful completion of their collaboration.

• Ginkgo Bioworks and Syngenta Seeds Announce Collaboration to Develop New Traits for the Next Generation of Seed Technology

  4/17/2023

  Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, and Syngenta Seeds, one of the world's leading agricultural technology companies, announced a research partnership focused on screening a targeted genetic library for novel trait discovery.

• Ginkgo Bioworks and the Government of the Democratic Republic of the Congo Announce Plans to Develop and Implement New Biosecurity Capabilities in the Region

  4/14/2023

  Ginkgo Bioworks and the Institut National de la Recherche Biomédicale today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent of developing and implementing new biosecurity capabilities in Democratic Republic of the Congo.

• Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies

  4/13/2023

  University of Wisconsin-Madison, and Ginkgo Bioworks today announced a partnership to leverage Ginkgo's proprietary high-throughput combinatorial CAR discovery and screening platform with the aim of discovering next generation GD2 CAR T-cell therapies with improved persistence, proliferation, fitness, and other functional properties to improve efficacy for the treatment of solid tumors.

• Ginkgo Bioworks to Host Annual Ferment Conference

  4/12/2023

  Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment, on Wednesday, April 19, 2023 in Boston, MA.

• Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio's AAV Capsid Discovery and Engineering Platform Assets

  4/5/2023

  Ginkgo Bioworks announced the acquisition of StrideBio's adeno-associated virus capsid discovery and engineering platform assets with a secondary close scheduled upon the transfer of certain additional in-license agreements to Ginkgo.

• Solvay Announces Strategic Collaboration With Ginkgo Bioworks And Expands Its R&I Footprint In The United States

  4/4/2023

  Solvay, a leading science and materials company whose technologies bring benefits to many aspects of daily life, announced a strategic collaboration with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity.

• Sensible Biotechnologies Announces Partnership with Ginkgo Bioworks to Develop Novel mRNA Manufacturing Platform

  4/3/2023

  Sensible Biotechnologies, an early stage biotechnology company, announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity.

• Ginkgo Bioworks Announces Participation in Cowen's 43rd Annual Health Care Conference

  3/2/2023

  Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to participate in Cowen's 43rd Annual Health Care Conference.

• Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2022 Results Presentation

  2/22/2023

  Ginkgo Bioworks today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2022, on Wednesday, March 1, 2023, beginning at 4:30 p.m. ET.

• Zymtronix and Ginkgo Bioworks Announce Partnership to Produce Enzymes for the Industrialization of Cell-Free Biomanufacturing

  2/16/2023

  Zymtronix and Ginkgo Bioworks announced a partnership to optimize enzymes used in Zymtronix's proprietary cell-free platform for the production of important ingredients in food, agriculture, cosmetics and pharmaceuticals.

• Ginkgo Bioworks Announces Pathogen Monitoring Program at Kigali International Airport

  2/15/2023

  Ginkgo Bioworks and the Rwanda Biomedical Centre announced a one-year pathogen monitoring program at Rwanda's Kigali International Airport to identify new and emerging variants of SARS-CoV-2.

• Bioweg and Ginkgo Bioworks Announce Partnership to Develop Cost Effective and Efficacious Bio-Based Materials to Reduce the Use of Microplastic Pollutants

  2/6/2023

  Bioweg and Ginkgo Bioworks announced a collaboration to optimize the production of bacterial cellulose and to produce novel variants of cellulose with improved performance to serve a variety of end markets.